According to Market Research Future (MRFR), the global antibody drug conjugate market is estimated to acquire a substantial market value, developing at a significant CAGR during the forecast period. It represents an innovative application that is an amalgamation of unique, high specificity, characteristics, and anti-tumor activity of monoclonal antibodies.
As per the records of WHO, in 2015, 15% of women were lost to breast cancer globally. Further, the increasing awareness about the treatment with antibody is propelling the market. In addition, the surging population is likely to play a vital role in magnifying the market. Besides, the development in the medical field is driving the market substantially.
The global antibody drug conjugate market 2020 is rising at a swift pace owing to the rise in patient population battling cancer. The therapy can treat various types of cancer, such as breast cancer and endometrial cancer. Breast cancer is one of the most common forms of cancer attacking women.
Based on the region, the global antibody drug conjugate market is segmented into America, Europe, Asia-Pacific, and the Middle East and Africa. As per the research, the global market is estimated to be commanded by the Americas due to technological innovation, development in the manufacturing method, and the participation of nanotechnology for developing Antibody Drug Conjugates (ADC). In the region, the US is recognized to acquire the largest market among other countries such as Canada and Mexico.
Europe is expected to acquire the second position. It is expected to be one of the most lucrative markets due to a large number of cancer patients in the region. Further, the participation of the government is estimated to fuel the market further.
The application-based segments of the global antibody drug conjugate market are prostate cancer, leukemia, kidney cancer, ovary cancer, pancreas cancer, glioblastoma, colon cancer, lung cancer, breast cancer, solid tumors, skin cancer, multiple myeloma, lymphoma, and other cancers
Be the first to comment
Sign in with